Universidad de Alcalá

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Universidad de Alcalá
Short name
UAH
Country, city
Spain, Madrid
Publications
20 156
Citations
432 494
h-index
194
Top-3 journals
Medicine (Barcelona)
Medicine (Barcelona) (517 publications)
Sensors
Sensors (207 publications)
Top-3 organizations
Top-3 foreign organizations
University of Lisbon
University of Lisbon (206 publications)
Sorbonne University
Sorbonne University (156 publications)
University of Oxford
University of Oxford (152 publications)

Most cited in 5 years

Klionsky D.J., Abdel-Aziz A.K., Abdelfatah S., Abdellatif M., Abdoli A., Abel S., Abeliovich H., Abildgaard M.H., Abudu Y.P., Acevedo-Arozena A., Adamopoulos I.E., Adeli K., Adolph T.E., Adornetto A., Aflaki E., et. al.
Autophagy scimago Q1 wos Q1 Open Access
2021-01-02 citations by CoLab: 1826 Abstract  
ABSTRACT In 2008, we published the first set of guidelines for standardizing research in autophagy. Since then, this topic has received increasing attention, and many scientists have entered the field. Our knowledge base and relevant new technologies have also been expanding. Thus, it is important to formulate on a regular basis updated guidelines for monitoring autophagy in different organisms. Despite numerous reviews, there continues to be confusion regarding acceptable methods to evaluate autophagy, especially in multicellular eukaryotes. Here, we present a set of guidelines for investigators to select and interpret methods to examine autophagy and related processes, and for reviewers to provide realistic and reasonable critiques of reports that are focused on these processes. These guidelines are not meant to be a dogmatic set of rules, because the appropriateness of any assay largely depends on the question being asked and the system being used. Moreover, no individual assay is perfect for every situation, calling for the use of multiple techniques to properly monitor autophagy in each experimental setting. Finally, several core components of the autophagy machinery have been implicated in distinct autophagic processes (canonical and noncanonical autophagy), implying that genetic approaches to block autophagy should rely on targeting two or more autophagy-related genes that ideally participate in distinct steps of the pathway. Along similar lines, because multiple proteins involved in autophagy also regulate other cellular pathways including apoptosis, not all of them can be used as a specific marker for bona fide autophagic responses. Here, we critically discuss current methods of assessing autophagy and the information they can, or cannot, provide. Our ultimate goal is to encourage intellectual and technical innovation in the field.
Kattge J., Bönisch G., Díaz S., Lavorel S., Prentice I.C., Leadley P., Tautenhahn S., Werner G.D., Aakala T., Abedi M., Acosta A.T., Adamidis G.C., Adamson K., Aiba M., Albert C.H., et. al.
Global Change Biology scimago Q1 wos Q1
2019-12-31 citations by CoLab: 1321 Abstract  
AbstractPlant traits—the morphological, anatomical, physiological, biochemical and phenological characteristics of plants—determine how plants respond to environmental factors, affect other trophic levels, and influence ecosystem properties and their benefits and detriments to people. Plant trait data thus represent the basis for a vast area of research spanning from evolutionary biology, community and functional ecology, to biodiversity conservation, ecosystem and landscape management, restoration, biogeography and earth system modelling. Since its foundation in 2007, the TRY database of plant traits has grown continuously. It now provides unprecedented data coverage under an open access data policy and is the main plant trait database used by the research community worldwide. Increasingly, the TRY database also supports new frontiers of trait‐based plant research, including the identification of data gaps and the subsequent mobilization or measurement of new data. To support this development, in this article we evaluate the extent of the trait data compiled in TRY and analyse emerging patterns of data coverage and representativeness. Best species coverage is achieved for categorical traits—almost complete coverage for ‘plant growth form’. However, most traits relevant for ecology and vegetation modelling are characterized by continuous intraspecific variation and trait–environmental relationships. These traits have to be measured on individual plants in their respective environment. Despite unprecedented data coverage, we observe a humbling lack of completeness and representativeness of these continuous traits in many aspects. We, therefore, conclude that reducing data gaps and biases in the TRY database remains a key challenge and requires a coordinated approach to data mobilization and trait measurements. This can only be achieved in collaboration with other initiatives.
Doebele R.C., Drilon A., Paz-Ares L., Siena S., Shaw A.T., Farago A.F., Blakely C.M., Seto T., Cho B.C., Tosi D., Besse B., Chawla S.P., Bazhenova L., Krauss J.C., Chae Y.K., et. al.
The Lancet Oncology scimago Q1 wos Q1
2020-02-01 citations by CoLab: 1228 Abstract  
Summary Background Entrectinib is a potent inhibitor of tropomyosin receptor kinase (TRK) A, B, and C, which has been shown to have anti-tumour activity against NTRK gene fusion-positive solid tumours, including CNS activity due to its ability to penetrate the blood–brain barrier. We present an integrated efficacy and safety analysis of patients with metastatic or locally advanced solid tumours harbouring oncogenic NTRK1, NTRK2, and NTRK3 gene fusions treated in three ongoing, early-phase trials. Methods An integrated database comprised the pivotal datasets of three, ongoing phase 1 or 2 clinical trials (ALKA-372-001, STARTRK-1, and STARTRK-2), which enrolled patients aged 18 years or older with metastatic or locally advanced NTRK fusion-positive solid tumours who received entrectinib orally at a dose of at least 600 mg once per day in a capsule. All patients had an Eastern Cooperative Oncology Group performance status of 0–2 and could have received previous anti-cancer therapy (except previous TRK inhibitors). The primary endpoints, the proportion of patients with an objective response and median duration of response, were evaluated by blinded independent central review in the efficacy-evaluable population (ie, patients with NTRK fusion-positive solid tumours who were TRK inhibitor-naive and had received at least one dose of entrectinib). Overall safety evaluable population included patients from STARTRK-1, STARTRK-2, ALKA-372-001, and STARTRK-NG ( NCT02650401 ; treating young adult and paediatric patients [aged ≤21 years]), who received at least one dose of entrectinib, regardless of tumour type or gene rearrangement. NTRK fusion-positive safety evaluable population comprised all patients who have received at least one dose of entrectinib regardless of dose or follow-up. These ongoing studies are registered with ClinicalTrials.gov , NCT02097810 (STARTRK-1) and NCT02568267 (STARTRK-2), and EudraCT, 2012–000148–88 (ALKA-372-001). Findings Patients were enrolled in ALKA-372–001 from Oct 26, 2012, to March 27, 2018; in STARTRK-1 from Aug 7, 2014, to May 10, 2018; and in STARTRK-2 from Nov 19, 2015 (enrolment is ongoing). At the data cutoff date for this analysis (May 31, 2018) the efficacy-evaluable population comprised 54 adults with advanced or metastatic NTRK fusion-positive solid tumours comprising ten different tumour types and 19 different histologies. Median follow-up was 12.9 months (IQR 8·77–18·76). 31 (57%; 95% CI 43·2–70·8) of 54 patients had an objective response, of which four (7%) were complete responses and 27 (50%) partial reponses. Median duration of response was 10 months (95% CI 7·1 to not estimable). The most common grade 3 or 4 treatment-related adverse events in both safety populations were increased weight (seven [10%] of 68 patients in the NTRK fusion-positive safety population and in 18 [5%] of 355 patients in the overall safety-evaluable population) and anaemia (8 [12%] and 16 [5%]). The most common serious treatment-related adverse events were nervous system disorders (three [4%] of 68 patients and ten [3%] of 355 patients). No treatment-related deaths occurred. Interpretation Entrectinib induced durable and clinically meaningful responses in patients with NTRK fusion-positive solid tumours, and was well tolerated with a manageable safety profile. These results show that entrectinib is a safe and active treatment option for patients with NTRK fusion-positive solid tumours. These data highlight the need to routinely test for NTRK fusions to broaden the therapeutic options available for patients with NTRK fusion-positive solid tumours. Funding Ignyta/F Hoffmann-La Roche.
Wilkinson J.L., Boxall A.B., Kolpin D.W., Leung K.M., Lai R.W., Galbán-Malagón C., Adell A.D., Mondon J., Metian M., Marchant R.A., Bouzas-Monroy A., Cuni-Sanchez A., Coors A., Carriquiriborde P., Rojo M., et. al.
2022-02-14 citations by CoLab: 832 Abstract  
Significance Despite growing evidence of the deleterious effects on ecological and human health, little is known regarding the global occurrence of pharmaceuticals in rivers. Studies assessing their occurrence are available for 75 of 196 countries, with most research conducted in North America and Western Europe. This leaves large geographical regions relatively unstudied. Here, we present the findings of a global reconnaissance of pharmaceutical pollution in rivers. The study monitored 1,052 sampling sites along 258 rivers in 104 countries of all continents, thus representing the pharmaceutical fingerprint of 471.4 million people. We show that the presence of these contaminants in surface water poses a threat to environmental and/or human health in more than a quarter of the studied locations globally.
Strangfeld A., Schäfer M., Gianfrancesco M.A., Lawson-Tovey S., Liew J.W., Ljung L., Mateus E.F., Richez C., Santos M.J., Schmajuk G., Scirè C.A., Sirotich E., Sparks J.A., Sufka P., Thomas T., et. al.
2021-01-27 citations by CoLab: 496 Abstract  
ObjectivesTo determine factors associated with COVID-19-related death in people with rheumatic diseases.MethodsPhysician-reported registry of adults with rheumatic disease and confirmed or presumptive COVID-19 (from 24 March to 1 July 2020). The primary outcome was COVID-19-related death. Age, sex, smoking status, comorbidities, rheumatic disease diagnosis, disease activity and medications were included as covariates in multivariable logistic regression models. Analyses were further stratified according to rheumatic disease category.ResultsOf 3729 patients (mean age 57 years, 68% female), 390 (10.5%) died. Independent factors associated with COVID-19-related death were age (66–75 years: OR 3.00, 95% CI 2.13 to 4.22; >75 years: 6.18, 4.47 to 8.53; both vs ≤65 years), male sex (1.46, 1.11 to 1.91), hypertension combined with cardiovascular disease (1.89, 1.31 to 2.73), chronic lung disease (1.68, 1.26 to 2.25) and prednisolone-equivalent dosage >10 mg/day (1.69, 1.18 to 2.41; vs no glucocorticoid intake). Moderate/high disease activity (vs remission/low disease activity) was associated with higher odds of death (1.87, 1.27 to 2.77). Rituximab (4.04, 2.32 to 7.03), sulfasalazine (3.60, 1.66 to 7.78), immunosuppressants (azathioprine, cyclophosphamide, ciclosporin, mycophenolate or tacrolimus: 2.22, 1.43 to 3.46) and not receiving any disease-modifying anti-rheumatic drug (DMARD) (2.11, 1.48 to 3.01) were associated with higher odds of death, compared with methotrexate monotherapy. Other synthetic/biological DMARDs were not associated with COVID-19-related death.ConclusionAmong people with rheumatic disease, COVID-19-related death was associated with known general factors (older age, male sex and specific comorbidities) and disease-specific factors (disease activity and specific medications). The association with moderate/high disease activity highlights the importance of adequate disease control with DMARDs, preferably without increasing glucocorticoid dosages. Caution may be required with rituximab, sulfasalazine and some immunosuppressants.
Sadeghipour P., Talasaz A.H., Rashidi F., Sharif-Kashani B., Beigmohammadi M.T., Farrokhpour M., Sezavar S.H., Payandemehr P., Dabbagh A., Moghadam K.G., Jamalkhani S., Khalili H., Yadollahzadeh M., Riahi T., Rezaeifar P., et. al.
2021-04-27 citations by CoLab: 493 Abstract  
Importance Thrombotic events are commonly reported in critically ill patients with COVID-19. Limited data exist to guide the intensity of antithrombotic prophylaxis. Objective To evaluate the effects of intermediate-dose vs standard-dose prophylactic anticoagulation among patients with COVID-19 admitted to the intensive care unit (ICU). Design, Setting, and Participants Multicenter randomized trial with a 2 × 2 factorial design performed in 10 academic centers in Iran comparing intermediate-dose vs standard-dose prophylactic anticoagulation (first hypothesis) and statin therapy vs matching placebo (second hypothesis; not reported in this article) among adult patients admitted to the ICU with COVID-19. Patients were recruited between July 29, 2020, and November 19, 2020. The final follow-up date for the 30-day primary outcome was December 19, 2020. Interventions Intermediate-dose (enoxaparin, 1 mg/kg daily) (n = 276) vs standard prophylactic anticoagulation (enoxaparin, 40 mg daily) (n = 286), with modification according to body weight and creatinine clearance. The assigned treatments were planned to be continued until completion of 30-day follow-up. Main Outcomes and Measures The primary efficacy outcome was a composite of venous or arterial thrombosis, treatment with extracorporeal membrane oxygenation, or mortality within 30 days, assessed in randomized patients who met the eligibility criteria and received at least 1 dose of the assigned treatment. Prespecified safety outcomes included major bleeding according to the Bleeding Academic Research Consortium (type 3 or 5 definition), powered for noninferiority (a noninferiority margin of 1.8 based on odds ratio), and severe thrombocytopenia (platelet count <20 ×103/µL). All outcomes were blindly adjudicated. Results Among 600 randomized patients, 562 (93.7%) were included in the primary analysis (median [interquartile range] age, 62 [50-71] years; 237 [42.2%] women). The primary efficacy outcome occurred in 126 patients (45.7%) in the intermediate-dose group and 126 patients (44.1%) in the standard-dose prophylaxis group (absolute risk difference, 1.5% [95% CI, −6.6% to 9.8%]; odds ratio, 1.06 [95% CI, 0.76-1.48];P = .70). Major bleeding occurred in 7 patients (2.5%) in the intermediate-dose group and 4 patients (1.4%) in the standard-dose prophylaxis group (risk difference, 1.1% [1-sided 97.5% CI, −∞ to 3.4%]; odds ratio, 1.83 [1-sided 97.5% CI, 0.00-5.93]), not meeting the noninferiority criteria (Pfor noninferiority >.99). Severe thrombocytopenia occurred only in patients assigned to the intermediate-dose group (6 vs 0 patients; risk difference, 2.2% [95% CI, 0.4%-3.8%];P = .01). Conclusions and Relevance Among patients admitted to the ICU with COVID-19, intermediate-dose prophylactic anticoagulation, compared with standard-dose prophylactic anticoagulation, did not result in a significant difference in the primary outcome of a composite of adjudicated venous or arterial thrombosis, treatment with extracorporeal membrane oxygenation, or mortality within 30 days. These results do not support the routine empirical use of intermediate-dose prophylactic anticoagulation in unselected patients admitted to the ICU with COVID-19. Trial Registration ClinicalTrials.gov Identifier:NCT04486508
Garassino M.C., Whisenant J.G., Huang L., Trama A., Torri V., Agustoni F., Baena J., Banna G., Berardi R., Bettini A.C., Bria E., Brighenti M., Cadranel J., De Toma A., Chini C., et. al.
The Lancet Oncology scimago Q1 wos Q1
2020-07-01 citations by CoLab: 481 Abstract  
SummaryBackground Early reports on patients with cancer and COVID-19 have suggested a high mortality rate compared with the general population. Patients with thoracic malignancies are thought to be particularly susceptible to COVID-19 given their older age, smoking habits, and pre-existing cardiopulmonary comorbidities, in addition to cancer treatments. We aimed to study the effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on patients with thoracic malignancies. Methods The Thoracic Cancers International COVID-19 Collaboration (TERAVOLT) registry is a multicentre observational study composed of a cross-sectional component and a longitudinal cohort component. Eligibility criteria were the presence of any thoracic cancer (non-small-cell lung cancer [NSCLC], small-cell lung cancer, mesothelioma, thymic epithelial tumours, and other pulmonary neuroendocrine neoplasms) and a COVID-19 diagnosis, either laboratory confirmed with RT-PCR, suspected with symptoms and contacts, or radiologically suspected cases with lung imaging features consistent with COVID-19 pneumonia and symptoms. Patients of any age, sex, histology, or stage were considered eligible, including those in active treatment and clinical follow-up. Clinical data were extracted from medical records of consecutive patients from Jan 1, 2020, and will be collected until the end of pandemic declared by WHO. Data on demographics, oncological history and comorbidities, COVID-19 diagnosis, and course of illness and clinical outcomes were collected. Associations between demographic or clinical characteristics and outcomes were measured with odds ratios (ORs) with 95% CIs using univariable and multivariable logistic regression, with sex, age, smoking status, hypertension, and chronic obstructive pulmonary disease included in multivariable analysis. This is a preliminary analysis of the first 200 patients. The registry continues to accept new sites and patient data. Findings Between March 26 and April 12, 2020, 200 patients with COVID-19 and thoracic cancers from eight countries were identified and included in the TERAVOLT registry; median age was 68·0 years (61·8–75·0) and the majority had an Eastern Cooperative Oncology Group performance status of 0–1 (142 [72%] of 196 patients), were current or former smokers (159 [81%] of 196), had non-small-cell lung cancer (151 [76%] of 200), and were on therapy at the time of COVID-19 diagnosis (147 [74%] of 199), with 112 (57%) of 197 on first-line treatment. 152 (76%) patients were hospitalised and 66 (33%) died. 13 (10%) of 134 patients who met criteria for ICU admission were admitted to ICU; the remaining 121 were hospitalised, but were not admitted to ICU. Univariable analyses revealed that being older than 65 years (OR 1·88, 95% 1·00–3·62), being a current or former smoker (4·24, 1·70–12·95), receiving treatment with chemotherapy alone (2·54, 1·09–6·11), and the presence of any comorbidities (2·65, 1·09–7·46) were associated with increased risk of death. However, in multivariable analysis, only smoking history (OR 3·18, 95% CI 1·11–9·06) was associated with increased risk of death. Interpretation With an ongoing global pandemic of COVID-19, our data suggest high mortality and low admission to intensive care in patients with thoracic cancer. Whether mortality could be reduced with treatment in intensive care remains to be determined. With improved cancer therapeutic options, access to intensive care should be discussed in a multidisciplinary setting based on cancer specific mortality and patients' preference. Funding None.
Edo C., González-Pleiter M., Leganés F., Fernández-Piñas F., Rosal R.
Environmental Pollution scimago Q1 wos Q1
2020-04-01 citations by CoLab: 414 Abstract  
This work studied the occurrence of microplastics in primary and secondary effluents and mixed sludge of a WWTP as well as in processed heat-dried sludge marketed as soil amendment. Sampled microparticles were divided into fragments and fibres, the latter defined as those with cylindrical shape and length to diameter ratio >3. We showed the presence of 12 different anthropogenic polymers or groups of polymers with a predominance of polyethylene, polypropylene, polyester and acrylic fibres together with an important amount of manufactured natural fibres. The smaller sampled fraction, in the 25-104 μm range, was the largest in both primary and secondary effluents. Fibres displayed lower sizes than fragments and represented less than one third of the anthropogenic particles sampled in effluents but up to 84% of heat-dried sludge. The plant showed a high efficiency (>90%) in removing microplastics from wastewater. However, the amount of anthropogenic plastics debris in the 25 μm - 50 mm range still released with the effluent amounted to 12.8 ± 6.3 particles/L, representing 300 million plastic debris per day and an approximate load of microplastics of 350 particles/m3 in the receiving Henares River. WWTP mixed sludge contained 183 ± 84 particles/g while heat-dried sludge bore 165 ± 37 particles/g. The sludge of the WWTP sampled in this work, would disseminate 8 × 1011 plastic particles per year if improperly managed. The agricultural use of sludge as soil amendment in the area of Madrid could spread up to 1013 microplastic particles in agricultural soils per year.
Jiménez D., García-Sanchez A., Rali P., Muriel A., Bikdeli B., Ruiz-Artacho P., Le Mao R., Rodríguez C., Hunt B.J., Monreal M.
Chest scimago Q1 wos Q1
2021-03-01 citations by CoLab: 366 Abstract  
Background Individual studies have reported widely variable rates for VTE and bleeding among hospitalized patients with coronavirus disease 2019 (COVID-19). Research Question What is the incidence of VTE and bleeding among hospitalized patients with COVID-19? Methods In this systematic review and meta-analysis, 15 standard sources and COVID-19-specific sources were searched between January 1, 2020, and July 31, 2020, with no restriction according to language. Incidence estimates were pooled by using random effects meta-analyses. Heterogeneity was evaluated by using the I2 statistic, and publication bias was assessed by using the Begg and Egger tests. Results The pooled incidence was 17.0% (95% CI, 13.4-20.9) for VTE, 12.1% (95% CI, 8.4-16.4) for DVT, 7.1% (95% CI, 5.3-9.1) for pulmonary embolism (PE), 7.8% (95% CI, 2.6-15.3) for bleeding, and 3.9% (95% CI, 1.2-7.9) for major bleeding. In subgroup meta-analyses, the incidence of VTE was higher when assessed according to screening (33.1% vs 9.8% by clinical diagnosis), among patients in the ICU (27.9% vs 7.1% in the ward), in prospective studies (25.5% vs 12.4% in retrospective studies), and with the inclusion of catheter-associated thrombosis/isolated distal DVTs and isolated subsegmental PEs. The highest pooled incidence estimate of bleeding was reported for patients receiving intermediate- or full-dose anticoagulation (21.4%) and the lowest in the only prospective study that assessed bleeding events (2.7%). Interpretation Among hospitalized patients with COVID-19, the overall estimated pooled incidence of VTE was 17.0%, with higher rates with routine screening, inclusion of distal DVT, and subsegmental PE, in critically ill patients and in prospective studies. Bleeding events were observed in 7.8% of patients and were sensitive to use of escalated doses of anticoagulants and nature of data collection. Additional studies are required to ascertain the significance of various thrombotic events and to identify strategies to improve patient outcomes. Trial Registry PROSPERO; No.: CRD42020198864; URL: https://www.crd.york.ac.uk/prospero/.
de Abajo F.J., Rodríguez-Martín S., Lerma V., Mejía-Abril G., Aguilar M., García-Luque A., Laredo L., Laosa O., Centeno-Soto G.A., Ángeles Gálvez M., Puerro M., González-Rojano E., Pedraza L., de Pablo I., Abad-Santos F., et. al.
The Lancet scimago Q1 wos Q1 Open Access
2020-05-15 citations by CoLab: 302 Abstract  
SummaryBackground Concerns have been raised about the possibility that inhibitors of the renin–angiotensin–aldosterone system (RAAS) could predispose individuals to severe COVID-19; however, epidemiological evidence is lacking. We report the results of a case-population study done in Madrid, Spain, since the outbreak of COVID-19. Methods In this case-population study, we consecutively selected patients aged 18 years or older with a PCR-confirmed diagnosis of COVID-19 requiring admission to hospital from seven hospitals in Madrid, who had been admitted between March 1 and March 24, 2020. As a reference group, we randomly sampled ten patients per case, individually matched for age, sex, region (ie, Madrid), and date of admission to hospital (month and day; index date), from Base de datos para la Investigación Farmacoepidemiológica en Atención Primaria (BIFAP), a Spanish primary health-care database, in its last available year (2018). We extracted information on comorbidities and prescriptions up to the month before index date (ie, current use) from electronic clinical records of both cases and controls. The outcome of interest was admission to hospital of patients with COVID-19. To minimise confounding by indication, the main analysis focused on assessing the association between COVID-19 requiring admission to hospital and use of RAAS inhibitors compared with use of other antihypertensive drugs. We calculated odds ratios (ORs) and 95% CIs, adjusted for age, sex, and cardiovascular comorbidities and risk factors, using conditional logistic regression. The protocol of the study was registered in the EU electronic Register of Post-Authorisation Studies, EUPAS34437. Findings We collected data for 1139 cases and 11 390 population controls. Among cases, 444 (39·0%) were female and the mean age was 69·1 years (SD 15·4), and despite being matched on sex and age, a significantly higher proportion of cases had pre-existing cardiovascular disease (OR 1·98, 95% CI 1·62–2·41) and risk factors (1·46, 1·23–1·73) than did controls. Compared with users of other antihypertensive drugs, users of RAAS inhibitors had an adjusted OR for COVID-19 requiring admission to hospital of 0·94 (95% CI 0·77–1·15). No increased risk was observed with either angiotensin-converting enzyme inhibitors (adjusted OR 0·80, 0·64–1·00) or angiotensin-receptor blockers (1·10, 0·88–1·37). Sex, age, and background cardiovascular risk did not modify the adjusted OR between use of RAAS inhibitors and COVID-19 requiring admission to hospital, whereas a decreased risk of COVID-19 requiring admission to hospital was found among patients with diabetes who were users of RAAS inhibitors (adjusted OR 0·53, 95% CI 0·34–0·80). The adjusted ORs were similar across severity degrees of COVID-19. Interpretation RAAS inhibitors do not increase the risk of COVID-19 requiring admission to hospital, including fatal cases and those admitted to intensive care units, and should not be discontinued to prevent a severe case of COVID-19. Funding Instituto de Salud Carlos III.
Fraile-Martinez O., García-Montero C., Pekarek T., Bujan J., Barrena-Blázquez S., Pena-Burgos E.M., López-González L., Pekarek L., Díaz-Pedrero R., De León-Luis J.A., Bravo C., Álvarez-Mon M., Saez M.A., García-Honduvilla N., Ortega M.A.
2025-03-09 citations by CoLab: 0 PDF Abstract  
Background: Chronic venous disease (CVD) is a vascular disorder common among pregnant women, due to the impairment in the venous function associated with the mechanical, hemodynamical, and hormonal changes that occur during pregnancy. CVD is linked to venous hypertension, inflammation, oxidative stress, and hypoxia, which alter placental structure and function, as demonstrated in previous works. The placenta fulfills several roles in fetal development and maternal well-being by mediating nutrient exchange; acting as a mechanical, chemical, and immunological shield; and producing essential hormones, making it crucial to investigate the effects of CVD in this organ. Patients and methods: This work specifically analyzes the gene expression of circadian markers (CLOCK, BMAL1, PER1, and PER2), epigenetic regulators (HAT1 and associated molecules like histones H3, H4, RBBP7, and ASF1), and the anti-aging protein KLOTHO in placental tissue of pregnant women with CVD (CVD-PW, N = 98) compared to healthy pregnant controls (HC-PW, N = 82), using RT-qPCR and immunohistochemistry (IHC) to determine protein expression. Results: Our study demonstrates that the placentas of CVD-PW exhibit the reduced gene and protein levels of circadian regulators (clock, bmal1, per1, and per2), increased expression of hat1 and related proteins (h3, h4, rbbp7, and asf1), and decreased klotho expression, indicative of accelerated aging. Conclusions: These findings highlight profound molecular disturbances in the placentas of women with CVD, offering insights into the disease’s pathophysiology and potential implications for maternofetal well-being. While this study deepens our understanding of the relationship between CVD and placental dysfunction, further research is required to fully elucidate these mechanisms and their long-term effects.
Cáceres Estévez I., Haya Rodriguez L., Haro Perdiguero E., Moreno Tovar F.J., Montalvo Lobo D., Nieto Botella L., González S., López Sánchez A.
2025-03-05 citations by CoLab: 0 PDF Abstract  
There is a need for new technologies in photoprotection. The negative effects of solar exposure on the skin have been amply demonstrated and there is an urgency for the development of alternative photoprotective approaches. In this respect, natural extracts represent the most interesting and promising source. Among them, Aspalathus linearis extracts appear to be an excellent candidate due to supporting evidence, their multiple beneficial biological effects, and their robust toxicological profile. Here, we first explored the photoprotective properties of two different Aspalathus linearis extracts (fermented and unfermented) individually, and then in combination, in a simplified model assessing Normal Human Dermal Fibroblast survival after UVB radiation. Surprisingly, we found the fermented extract to be more photoprotective than the unfermented one. In addition, a specific combination of the two extracts showed a synergistic effect. By HPLC and FRAP analyses, we observed that the photoprotective effect did not correlate with the amount of Aspalathus linearis main characteristic metabolites nor with the antioxidant capacity of the ingredients. Finally, an additional photoprotective effect was observed when Aspalathus linearis extracts were combined with a Polypodium leucotomos extract (Fernblock®), a well-known botanical ingredient with demonstrated photoprotection activities. Thus, this work provides a solid scientific basis for the inclusion of this technology in future topical and systemic photoprotective strategies.
Téllez L., Rincón D., Payancé A., Jaillais A., Lebray P., Rodríguez de Santiago E., Clemente A., Paradis V., Lefort B., Garrido-Lestache E., Prieto R., Iserin L., Tallegas M., Garrido E., Torres M., et. al.
Journal of Hepatology scimago Q1 wos Q1
2025-03-01 citations by CoLab: 1 Abstract  
Fontan-type surgery is used as a palliation for congenital heart disease with univentricular physiology but may, in the long term, lead to advanced chronic liver disease. This study assessed the accuracy of conventional non-invasive models in assessing liver fibrosis and introduces a new risk score employing non-invasive tools.
Pérez Expósito R.E., Ortega Núñez M.A., Buján Varela M.J., Vega Rodríguez R.M., Ortíz Chércoles A.I., La Torre Escuredo B.J.
2025-03-01 citations by CoLab: 0 Abstract  
Objetivo: evaluar con un modelo animal de osteoartrosis (conejos raza Nueva Zelanda) la eficacia del tratamiento con viscosuplementos activos (ácido hialurónico cargado con nanopartículas (NPs) que encapsulan compuestos o fármacos antiinflamatorios. Material y métodos: estudio experimental compuesto de 5 grupos de conejos a los que se realizó la sección del ligamento cruzado anterior y resección del menisco interno para desencadenar cambios degenerativos y usarlo como modelo de osteoartrosis. Los grupos se dividieron en osteoartrosis sin tratamiento (I), tratamiento con ácido hialurónico (AH) comercial (II), tratamiento con AH con nanopartículas vacías (III), tratamiento con AH con nanopartículas que encapsulan dexametasona (IV) y tratamiento con AH con nanopartículas que encapsulan cúrcuma (V). En los grupos II a V se realizó la infiltración del compuesto correspondiente espaciándolas una semana.Se realizó un análisis histológico macroscópico mediante una escala basada en la clasificación de Outerbridge para la artrosis. Resultados: Observamos que dicho modelo de osteoartrosis es reproducible y se aprecian cambios degenerativos similares a los que se encuentran en el ser humano. Los grupos a los que se infiltró ácido hialurónico con nanopartículas cargadas con curcumina (V), seguido del grupo de dexametasona (IV) presentaron macroscópicamente menos fibrilación, exposición de hueso subcondral y esclerosis (mejor puntuación en la escala) que los grupos de control (I) (osteoartrosis sin tratamiento), el grupo (II) tratado con ácido hialurónico comercial y el de ácido hialurónico con nanopartículas sin fármaco (III). Conclusiones: El uso de viscosuplementos activos podría tener un efecto adicional al tratamiento convencional de ácido hialurónico por su efecto antioxidante y antiinflamatorio, siendo el grupo más prometedor el de las nanopartículas que encapsulan curcumina y en segundo lugar el de dexametasona. Objective: to evaluate with an animal model of osteoarthritis (New Zealand rabbits) the effectiveness of treatment with active viscosupplements (hyaluronic acid loaded with nanoparticles (NPs) that encapsulate anti-inflammatory compounds or drugs. Material and methods: experimental study composed of 5 groups of rabbits in which section of the anterior cruciate ligament and resection of the internal meniscus were performed to trigger degenerative changes and use it as a model of osteoarthritis. The groups were divided into osteoarthrosis without treatment (I), treatment with commercial hyaluronic acid (HA) (II), treatment with HA with empty nanoparticles (III), treatment with HA with nanoparticles encapsulating dexamethasone (IV) and treatment with HA with nanoparticles that encapsulate curcumin (V). In groups II to V, the infiltration of the corresponding compound was carried out spaced one week apart.Macroscopic histological analysis was performed using a scale based on the Outerbridge classification for osteoarthritis. Results: We observed that this osteoarthritis model is reproducible and degenerative changes similar to those found in humans are observed.The groups that were infiltrated with hyaluronic acid with curcumin-loaded nanoparticles (V), followed by the dexamethasone group (IV) presented macroscopically less fibrillation, exposure of subchondral bone and sclerosis (better score on the scale) than the control groups (I) (osteoarthritis without treatment), group (II) treated with commercial hyaluronic acid and hyaluronic acid with nanoparticles without drug (III). Conclusions: The use of active viscosupplements could have an additional effect to conventional hyaluronic acid treatment due to its antioxidant and anti-inflammatory effect. The most promising group was hyaluronic acid with nanoparticles that encapsulate curcumin and the second group was the one that encapsulates dexamethasone.
Collaboration L., Aaij R., Abdelmotteleb A.S., Abellan Beteta C., Abudinèn F.J., Ackernley T., Adefisoye A.M., Adeva B., Adinolfi M., Adlarson P.H., Agapopoulou C., Aidala C., Ajaltouni Z., Akar S., Akiba K., et. al.
SciPost Physics scimago Q1 wos Q1 Open Access
2025-02-26 citations by CoLab: 0 Abstract  
Measurements are presented of the cross-section for the central exclusive production of J/\psi\to\mu^+\mu^-J/ψ→μ+μ− and \psi(2S)\to\mu^+\mu^-ψ(2S)→μ+μ− processes in proton-proton collisions at \sqrt{s} = 13 \ \mathrm{TeV}s=13TeV with 2016–2018 data. They are performed by requiring both muons to be in the LHCb acceptance (with pseudorapidity 2<\eta_{\mu^±} < 4.52<ημ±<4.5) and mesons in the rapidity range 2.0 < y < 4.52.0<y<4.5. The integrated cross-section results are \sigma_{J/\psi\to\mu^+\mu^-}(2.0<y_{J/\psi}<4.5,2.0<\eta_{\mu^{±}} < 4.5) = 400 ± 2 ± 5 ± 12 \mathrm{pb}, \ \sigma_{\psi(2S)\to\mu^+\mu^-}(2.0<y_{\psi(2S)}<4.5,2.0<\eta_{\mu^{±}} < 4.5) = 9.40 ± 0.15 ± 0.13 ± 0.27 \mathrm{pb},σJ/ψ→μ+μ−(2.0<yJ/ψ<4.5,2.0<ημ±<4.5)=400±2±5±12pb,σψ(2S)→μ+μ−(2.0<yψ(2S)<4.5,2.0<ημ±<4.5)=9.40±0.15±0.13±0.27pb, where the uncertainties are statistical, systematic and due to the luminosity determination. In addition, a measurement of the ratio of \psi(2S)ψ(2S) and J/\psiJ/ψ cross-sections, at an average photon-proton centre-of-mass energy of 1\ \mathrm{TeV}1TeV, is performed, giving$ = 0.1763 ± 0.0029 ± 0.0008 ± 0.0039,$ where the first uncertainty is statistical, the second systematic and the third due to the knowledge of the involved branching fractions. For the first time, the dependence of the J/\psiJ/ψ and \psi(2S)ψ(2S) cross-sections on the total transverse momentum transfer is determined in pppp collisions and is found consistent with the behaviour observed in electron-proton collisions.
Romano E., Domínguez-Rodríguez G., Mannina L., Cifuentes A., Ibáñez E.
Applied Sciences (Switzerland) scimago Q2 wos Q2 Open Access
2025-02-25 citations by CoLab: 0 PDF Abstract  
This study introduces a novel pressurized liquid extraction (PLE) strategy utilizing biobased solvents to simultaneously extract non-polar and polar compounds with antioxidant and anticholinergic properties from burdock roots. The influence of altitude and weeding on the bioactive composition of three burdock root ecotypes was evaluated: two from 150 m (one subjected to weeding during growth and another not subjected to weeding) and one from 800 m without weeding. A simplex-centroid mixture design identified 100% 2-methyltetrahydrofuran as the optimal solvent for PLE, offering superior extraction of bioactive compounds due to its ability to form strong hydrogen bonds with phenolic groups. Extraction at 100 °C was found to be optimal, avoiding the low yields and undesirable reactions observed at 40 °C and 160 °C, respectively. Altitude emerged as the most significant factor influencing bioactivity and composition, with roots from 800 m exhibiting the highest bioactivity. Key bioactive compounds included caffeoylquinic acids, caryophyllene oxide, spathulenol, and bisnorallocholanic acid. At 150 m, weeding reduced anticholinergic capacity but increased antioxidant synthesis, though the levels were lower than those observed at higher altitudes. These findings highlight that burdock roots grown at high altitudes without weeding produce extracts rich in antioxidant and neuroprotective compounds, offering significant potential for functional ingredient development.
Celiberto F.G., Gatto G.
Physical Review D scimago Q1 wos Q1
2025-02-24 citations by CoLab: 1 Abstract  
We study the semi-inclusive hadroproduction of doubly bottomed tetraquarks (Xbb¯qq¯) as well as fully bottomed ones (T4b), to which we collectively refer as “bottomoniumlike” states. We rely upon the variable-flavor number-scheme fragmentation at leading power, where a single parton perturbatively splits into the corresponding Fock state, which then hadronizes into the color-neutral, observed tetraquark. To this end, we build new sets of /-evo consistent, hadron-structure oriented collinear fragmentation functions, which we name and parametrizations. They extend and supersede the corresponding versions recently derived in previous works. The first family describes the fragmentation of doubly heavy tetraquarks and is based on an improved version of the Suzuki model for the heavy-quark channel. The second family depicts the fragmentation of fully heavy tetraquarks and embodies initial-scale inputs for gluon and heavy-quark channels, both of them calculated by the hands of potential nonrelativistic QCD. As a phenomenological application, we provide novel predictions for tetraquark-plus-jet high-energy distributions, computed within the NLL/NLO+ hybrid factorization from (sym), at 14 and 100 TeV FCC. Published by the American Physical Society 2025
Lancharro Zapata Á., Aguado del Hoyo A., Sánchez Gómez de Orgaz M.D., Ortega M.A., León Luís J.A.
Journal of Clinical Medicine scimago Q1 wos Q1 Open Access
2025-02-21 citations by CoLab: 0 PDF Abstract  
Background/Objectives: Liver elastography is increasingly used in neonatal intensive care units (NICUs) as a non-invasive, radiation-free, reproducible technique for assessing liver stiffness. This technique demonstrates substantial advantages over conventional ultrasound in diagnosing diffuse liver diseases by providing quantitative measures of tissue elasticity. This article aims to describe the most critical milestones for performing liver elastography ultrasound point-of-care, a tool increasingly used to complement traditional ultrasound in the study of the liver in intensive care units where the population is very susceptible to manipulation. Methods: Techniques such as point-shear wave elastography (pSWE) and two-dimensional shear wave elastography (2D-SWE) have become key in evaluating conditions such as hypoxic-ischemic liver disease, cholestatic diseases, storage and metabolic disorders, or infectious liver conditions. However, despite its usefulness, performing elastography in neonates, particularly in those weighing less than 1000 g or in high-frequency oscillatory ventilation, presents notable challenges, including the extreme sensitivity of neonates to touch, noise, and temperature changes and the difficulty in obtaining accurate measurements due to limited hepatic depth. Results: Key factors for the success of sonoelastography in this population include minimizing contact time, adjusting mechanical and thermal indices to meet biosecurity guidelines, and ensuring patient comfort and stability during the procedure. Despite these challenges, elastography has proven helpful in routine clinical practice. Conclusions: The growing evidence on elastography has provided standardized reference values, further enhancing its clinical applicability in NICU settings.
Gallardo L.O., Aiger Vallés M., Cativiela-Campos B., Domingo-Valero L., Barrasa Á., Alique M., López-Granero C.
Frontiers in Pharmacology scimago Q1 wos Q1 Open Access
2025-02-17 citations by CoLab: 0 PDF Abstract  
Air pollution and its effects on population health are currently among the most important public health issues. It is well established that the impact of air pollution on health is exceedingly high, although it ignores its real scope and effects on the aging process because studies on air quality have largely focused on younger age groups. Herein, we emphasize the relevance of air quality to the behavioral aging process, taking into account the place of residence - rural or urban. We raise the following question: Can air quality and residential settings modulate cognitive, emotional and social behaviors during the aging? Some studies have analyzed the role of residential settings and air pollution in the context of a behavioral frame in elderly people. Based on the analyzed literature, this revision concluded that air pollutants affect cognitive function, increasing the risk of dementia as well as depression and anxiety emotional responses. In addition, social networks and inclusion can modulate and mitigate the effects observed during the aging in rural areas that are exposed to less contamination. Although there is no consensus, it seems that some observed behavioral effects are sex-dependent, as women are more vulnerable to air pollution. Additionally, we examined why older adults are vulnerable to the health effects of Particulate Matter (PM) exposure and highlighted the importance of social health in this context. Environmental agents could be the key to understanding the susceptibility and variability observed during aging in behavioral symptoms. Although cognitive decline is related to increased age, it is not a manipulated factor. Efforts should be centered on locating factors implicated in the aging process that could be susceptible to manipulation or variation, such as the choice of the place of residence and the air that we are breathing. Given the significant societal impact of PM, research and policy regulations should be closely aligned and collaborative.
Díez-Gutiérrez E., Trujillo Vargas J., Perlado-Lamo de Espinosa I., Palomo-Cermeño E., Mateos-Toro L., Pérez-Robles A., García-Salas L., Romero Acosta K.
Sustainability scimago Q1 wos Q2 Open Access
2025-02-17 citations by CoLab: 0 PDF Abstract  
The aim of this research is to find out whether education students and professionals are aware of the seriousness of climate change and the environmental crisis and whether they receive training to deal with it in their professional future. More specifically, this study aims to analyze if they are aware of the degrowth proposal and consider they should train themselves and future generations in it to tackle this ecosystemic crisis profoundly. The methodology used was qualitative, through focused semi-structured in-depth interviews. The results of the data analysis, carried out with Atlas.ti, are structured around four dimensions: (a) Climate change, sustainability-consumption-social implications, (b) Growth, degrowth, collapse, (c) Personal attitudes towards caring for the planet and (d) Educating/training for degrowth. It is concluded that there is a general awareness concerning degrowth as a relevant issue and a possible alternative, but this is not applied in educational and curricular practice. The need to review the initial training plans for future teachers to introduce these elements is discussed. A limitation of this study is the scarcity of literature on degrowth in education and the need to expand the research sample in order to generalize the findings obtained in the research.
Sádaba-Campo N., Gómez-Moreno H.
2025-02-14 citations by CoLab: 0 PDF Abstract  
This article addresses the impact of generative artificial intelligence on the creation of composite sketches for police investigations. The automation of this task, traditionally performed through artistic methods or image composition, has become a challenge that can be tackled with generative neural networks. In this context, technologies such as Generative Adversarial Networks, Variational Autoencoders, and Diffusion Models are analyzed. The study also focuses on the use of advanced tools like DALL-E, Midjourney, and primarily Stable Diffusion, which enable the generation of highly detailed and realistic facial images from textual descriptions or sketches and allow for rapid and precise morphofacial modifications. Additionally, the study explores the capacity of these tools to interpret user-provided facial feature descriptions and adjust the generated results accordingly. The article concludes that these technologies have the potential to automate the composite sketch creation process. Therefore, their integration could not only expedite this process but also enhance its accuracy and utility in the identification of suspects or missing persons, representing a groundbreaking advancement in the field of criminal investigation.
Del Valle H., Rodríguez-Navarro A.B., Moclán A., García-Medrano P., Cáceres I.
Scientific Reports scimago Q1 wos Q1 Open Access
2025-02-14 citations by CoLab: 0 PDF Abstract  
Abstract Bone diagenesis is a complex process that modifies bone components in response to burial conditions. These modifications help to understand deposit formation and classify fossils by stratigraphy. The combined techniques of X-ray diffraction with Rietveld refinement and infrared spectroscopy were used to study the bone diagenetic processes along the complete stratigraphic sequence of Galería site (Sierra de Atapuerca, Spain). Eleven chemometric indices considering the different bone components (phosphates, carbonates, organic phase), together with the apatite unit cell parameters and cell volume were evaluated by 9 machine learning algorithms for bone diagenesis/stratigraphic classification. The results showed differences along the stratigraphic sequence due to changes in the apatite structure chemistry (i.e., F− and OH−), producing a gradual shift of the unit cell volume (from 531.9 to 526.1 Å3) from GII to GIV associated with coupled dissolution–precipitation processes. Two diagenetic pathways are indicated: The lowest unit (GII) is characterized by leaching and carbonate loss in bone, suggesting an acidic and wet burial environment with the formation of authigenic phosphate minerals. The uppermost units (GIII-GIV) show bone apatite undergoing F− and CO3 incorporation, suggesting a slightly alkaline and drier environment. These differences enabled the development of classification models to understand deposit formation dynamics and also recontextualize dissociated fossil bones.

Since 1968

Total publications
20156
Total citations
432494
Citations per publication
21.46
Average publications per year
353.61
Average authors per publication
9.95
h-index
194
Metrics description

Top-30

Fields of science

500
1000
1500
2000
2500
3000
3500
General Medicine, 3031, 15.04%
Biochemistry, 1637, 8.12%
Organic Chemistry, 1161, 5.76%
Analytical Chemistry, 952, 4.72%
Electrical and Electronic Engineering, 933, 4.63%
Physical and Theoretical Chemistry, 889, 4.41%
Ecology, Evolution, Behavior and Systematics, 810, 4.02%
Inorganic Chemistry, 680, 3.37%
Molecular Biology, 656, 3.25%
Computer Science Applications, 621, 3.08%
General Chemistry, 577, 2.86%
Materials Chemistry, 489, 2.43%
Ecology, 455, 2.26%
Cell Biology, 448, 2.22%
General Materials Science, 446, 2.21%
Instrumentation, 445, 2.21%
Atomic and Molecular Physics, and Optics, 439, 2.18%
Public Health, Environmental and Occupational Health, 416, 2.06%
Spectroscopy, 412, 2.04%
Pharmacology, 399, 1.98%
Genetics, 398, 1.97%
Environmental Chemistry, 398, 1.97%
Plant Science, 395, 1.96%
Cardiology and Cardiovascular Medicine, 395, 1.96%
Drug Discovery, 387, 1.92%
Condensed Matter Physics, 357, 1.77%
Clinical Biochemistry, 356, 1.77%
Multidisciplinary, 353, 1.75%
Infectious Diseases, 352, 1.75%
Pollution, 339, 1.68%
500
1000
1500
2000
2500
3000
3500

Journals

100
200
300
400
500
600
100
200
300
400
500
600

Publishers

1000
2000
3000
4000
5000
6000
7000
1000
2000
3000
4000
5000
6000
7000

With other organizations

200
400
600
800
1000
1200
1400
1600
1800
2000
200
400
600
800
1000
1200
1400
1600
1800
2000

With foreign organizations

50
100
150
200
250
50
100
150
200
250

With other countries

500
1000
1500
2000
2500
USA, 2090, 10.37%
United Kingdom, 1179, 5.85%
France, 1091, 5.41%
Germany, 1034, 5.13%
Italy, 942, 4.67%
Portugal, 611, 3.03%
Netherlands, 535, 2.65%
Switzerland, 515, 2.56%
Australia, 447, 2.22%
Sweden, 444, 2.2%
China, 443, 2.2%
Canada, 358, 1.78%
Brazil, 354, 1.76%
Poland, 322, 1.6%
Colombia, 292, 1.45%
Belgium, 290, 1.44%
Mexico, 282, 1.4%
Chile, 247, 1.23%
Austria, 224, 1.11%
Denmark, 223, 1.11%
Argentina, 216, 1.07%
Greece, 216, 1.07%
Norway, 185, 0.92%
Russia, 182, 0.9%
Japan, 173, 0.86%
Czech Republic, 154, 0.76%
India, 151, 0.75%
Iran, 150, 0.74%
Finland, 147, 0.73%
500
1000
1500
2000
2500
  • We do not take into account publications without a DOI.
  • Statistics recalculated daily.
  • Publications published earlier than 1968 are ignored in the statistics.
  • The horizontal charts show the 30 top positions.
  • Journals quartiles values are relevant at the moment.